S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ACET · Adicet Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$4.48
-0.01
(-0.22%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.48
$4.44
$4.59
52-WEEK RANGE
$4.48
$4.39
$16.48
What's happening
- ACET is down 0.22% today, trading at $4.48. — Live quote
- It's trading within 3% of its 52-week low ($4.39). (Finnhub fundamentals)
- Volume today (6,538) is well below its 3-month average of 160,480. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.99 actual vs. $-2.07 estimated (+4.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ACET
-46.32%
vs S&P 500
-59.10%
1-YEAR RETURN
ACET
-71.43%
vs S&P 500
-85.99%
6-MONTH RETURN
ACET
-43.85%
3-MONTH RETURN
ACET
-44.34%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.99
Est. $-2.07
BEAT +4.0%
2026-04-26 (Q1 2026)
$-1.88
Est. $-3.17
BEAT +40.7%
2026-01-26 (Q4 2025)
$-2.94
Est. $-2.86
MISS -2.9%
2025-10-26 (Q3 2025)
$-4.64
Est. $-4.73
BEAT +1.9%
Valuation Measures & Ratios
Enterprise Value4$9.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1.09
Price / Book70.67
EV4 / Revenue0.25
EV4 / EBITDA—
Profit Margin-93.15%
Operating Margin-91.40%
Return on Equity (ROE8)-74.90%
Return on Assets (ROA9)-60.87%
Avg Volume (3M)160,480
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $92.1M | $73.1M | $1.20B | $56.6M | $70.3M |
| P/E | -0.92 | -0.69 | -10.32 | -0.47 | -0.60 |
| Price/Book | 0.77 | 0.52 | 11.04 | 0.42 | 0.44 |
| ROE | -82.97% | -76.06% | -106.98% | -89.83% | -72.23% |
| ROA | -67.27% | -62.89% | -83.12% | -73.52% | -60.97% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short485,466
Change from Prior Settlement+78.49%
% of Float—
Days to Cover (Short Ratio)1.10
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-28; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -93.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ACET
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$22.3M | -$21.6M | -$28.0M | -$32.4M | -$29.9M | -$33.2M | -$32.8M | -$30.9M |
| Net income | -$21.4M | -$20.2M | -$26.9M | -$31.2M | -$28.2M | -$30.5M | -$29.9M | -$28.0M |
| EPS (diluted) | $-1.99 | $-1.88 | $-0.29 | $-5.48 | $-4.96 | $-0.34 | $-0.33 | $-0.35 |
| EPS (basic) | $-1.99 | $-1.88 | $-0.29 | $-5.48 | $-4.96 | $-0.34 | $-0.33 | $-0.35 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $148.2M | $169.4M | $192.4M | $140.5M | $163.0M | $191.3M | $220.2M | $246.0M |
| Total liabilities | $28.0M | $29.3M | $33.1M | $31.3M | $29.6M | $29.8M | $33.6M | $34.4M |
| Stockholders' equity | $120.1M | $140.1M | $159.2M | $109.1M | $133.4M | $161.4M | $186.6M | $211.5M |
| Total current assets | $120.8M | $140.1M | $160.9M | $106.5M | $127.7M | $153.6M | $180.1M | $206.3M |
| Total current liabilities | $18.0M | $18.3M | $21.5M | $18.9M | $17.1M | $16.4M | $19.4M | $19.4M |
| Cash & equivalents | $33.1M | $36.2M | $38.9M | $29.1M | $34.7M | $28.1M | $56.5M | $105.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | $96.6M |
| Other current assets | $441.0K | $348.0K | $314.0K | $619.0K | $690.0K | $478.0K | $737.0K | $543.0K |
| Property, plant & equipment | $14.0M | $15.2M | $16.5M | $18.0M | $19.5M | $21.1M | $22.5M | $24.1M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $80.0K | $78.0K | $76.0K | $110.0K | $225.0K | $314.0K | $428.0K | $508.0K |
| Accounts payable | $3.6M | $2.9M | $4.7M | $4.3M | $3.3M | $4.4M | $4.8M | $2.5M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $0 | $0 | $62.0K | $125.0K | $116.0K | $116.0K | $116.0K | $116.0K |
| Common stock & paid-in capital | $1.0K | $1.0K | $10.0K | $8.0K | $8.0K | $8.0K | $5.0K | $8.0K |
| Retained earnings | -$656.3M | -$634.9M | -$614.7M | -$584.2M | -$557.3M | -$526.1M | -$497.9M | -$469.2M |
| Accumulated other comprehensive income (loss) | -$105.0K | -$37.0K | $102.0K | $56.0K | -$41.0K | -$9.0K | $16.0K | $121.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.8M | -$21.5M | -$20.9M | -$22.3M | -$26.6M | -$25.4M | -$24.1M | -$22.0M |
| Investing cash flow | $16.7M | $18.9M | -$44.5M | $16.8M | $33.0M | -$2.9M | -$22.1M | -$96.6M |
| Financing cash flow | $58.0K | -$65.0K | $75.2M | -$150.0K | $267.0K | -$104.0K | $137.0K | $0 |
| Free cash flow | -$20.0M | -$21.5M | -$20.9M | -$22.5M | -$26.7M | -$26.9M | -$24.3M | -$22.4M |
| Capital expenditures | $202.0K | $37.0K | -$10.0K | $209.0K | $47.0K | $1.5M | $176.0K | $401.0K |
| Share-based compensation | $1.4M | $1.3M | $11.1M | $2.5M | $2.9M | $3.2M | $16.6M | $6.8M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $664.0K | -$1.8M | $307.0K | $1.2M | -$1.1M | $629.0K | $1.2M | $728.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $3.0K | $65.0K | $0 | — | — | $104.0K | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M |
| EPS (diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
| EPS (basic) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
| Stockholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M |
| Total current assets | $160.9M | $180.1M | $162.3M | $261.0M | $282.4M |
| Total current liabilities | $21.5M | $19.4M | $19.3M | $19.7M | $16.3M |
| Cash & equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M |
| Other current assets | $320.0K | $737.0K | $457.0K | $336.0K | $2.0K |
| Property, plant & equipment | $16.5M | $22.5M | $26.8M | $28.7M | $14.6M |
| Goodwill | — | — | $0 | $19.5M | $19.5M |
| Intangible assets | — | — | — | — | $0 |
| Other non-current assets | $76.0K | $428.0K | $822.0K | $1.2M | $1.9M |
| Accounts payable | $4.7M | $4.8M | $2.6M | $4.4M | $3.3M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | $0 | $4.8M |
| Other non-current liabilities | $62.0K | $116.0K | $130.0K | $114.0K | $115.0K |
| Common stock & paid-in capital | $10.0K | $5.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$614.7M | -$497.9M | -$380.8M | -$238.1M | -$168.3M |
| Accumulated other comprehensive income (loss) | $102.0K | $16.0K | $0 | $0 | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Investing cash flow | $2.4M | -$119.2M | -$4.5M | -$16.8M | -$2.8M |
| Financing cash flow | $75.2M | $111.3M | $236.0K | $41.5M | $242.7M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Capital expenditures | $1.7M | $1.1M | $4.5M | $16.8M | $13.0M |
| Share-based compensation | $14.3M | $22.2M | $20.3M | $17.1M | $12.5M |
| Deferred income taxes | $0 | $0 | $0 | $0 | -$125.0K |
| Change in accounts payable | $1.0M | $1.1M | -$1.7M | $1.7M | $1.1M |
| Purchases of investments | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | $0 | $2.8M |
| Tax withholding on stock comp | $104.0K | $141.0K | $150.0K | $3.2M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ACET as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 01:27 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-28 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-19 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-19 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-21 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-21 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-21 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-21 | View on SEC.gov → |
Recent news
Headlines about ACET (Adicet Bio, Inc.). Links open the publisher — we don’t host full articles.
-
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
Yahoo Finance · 2026-10-03 -
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - Slideshow
Seeking Alpha · 2026-09-30 -
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
Seeking Alpha · 2026-09-28 -
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
Yahoo Finance · 2026-09-28 -
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
Yahoo Finance · 2026-09-28 -
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Yahoo Finance · 2026-09-25 -
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
Yahoo Finance · 2026-09-03 -
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Yahoo Finance · 2026-09-03
No headlines in this category right now — try “All”.